What treatable traits should be addressed in a patient with a smoking history and diagnosed with chronic obstructive pulmonary disease (COPD)?

Treatable Traits in COPD Patients with Smoking History

In patients with COPD and a smoking history, the most critical treatable trait is active smoking cessation, followed by systematic identification and management of pulmonary traits (exacerbations, dyspnea, chronic bronchitis, blood eosinophilia), extra-pulmonary traits (comorbidities, nutritional status, physical inactivity), and behavioral traits (inhaler technique, medication adherence). 1

Priority Framework for Treatable Traits

1. Smoking Cessation (Highest Priority)

Smoking cessation is the single most impactful intervention that influences the natural history of COPD and must be addressed first. 1

• Pharmacotherapy approach:

  • Varenicline, bupropion, or nortriptyline combined with nicotine replacement therapy increases long-term quit rates to approximately 25% 1
  • These medications should be used as part of a comprehensive intervention program, not as sole therapy
  • E-cigarettes remain controversial with uncertain efficacy and safety 1

• Behavioral support:

  • Combination of pharmacotherapy with behavioral counseling significantly increases cessation rates compared to either alone 1
  • Five-step intervention programs delivered by healthcare professionals are more effective than self-initiated strategies 1

2. Pulmonary Treatable Traits

Frequent Exacerbations

• Patients with ≥2 exacerbations per year or ≥1 hospitalization require escalated therapy 2, 3
• This trait predicts future decline in lung function and quality of life 3

Chronic Bronchitis Phenotype

• Presence of chronic cough and sputum production is a distinct treatable trait 3, 4
• Associated with accelerated FEV1 decline (β -0.186) 3
• Requires phenotype-specific pharmacological interventions 4

Blood Eosinophilia

• Present in approximately 37% of COPD patients 5
• Predicts response to inhaled corticosteroids 5
• When eosinophilia is present and ICS is initiated/increased, significant reduction in this trait occurs (OR: 0.61) with improved health status 5

Dyspnea/Breathlessness

• Predicts decline in FEV1 (β -0.093) 3
• Requires optimization of bronchodilator therapy based on symptom severity 6, 1

3. Extra-Pulmonary Treatable Traits

Nutritional Status

• Underweight/Low BMI: Associated with significant FEV1 decline (β -0.216) and increased mortality 3
• Obesity: Present as a distinct treatable trait requiring intervention 5, 7
• Sarcopenia: Predicts FEV1 decline (β -0.162) 3

Physical Inactivity

• Common trait requiring pulmonary rehabilitation 5
• Pulmonary rehabilitation improves symptoms, quality of life, and physical/emotional participation in daily activities 1

Psychological Comorbidities

• Depression is the strongest predictor of quality of life decline (β -7.19) 3
• Anxiety and depression require systematic screening and treatment 2, 7
• Poor family/social support also strongly predicts QOL decline (β -5.12) 3

Cardiovascular and Other Comorbidities

• COPD is associated with significant concomitant chronic diseases that increase morbidity and mortality 1, 4
• Requires systematic assessment and management 6

4. Behavioral/Lifestyle Treatable Traits

Insufficient Inhaler Technique

• Present in 44% of patients—the most common treatable trait 5
• Inhaler technique must be assessed regularly 1
• Directly impacts medication efficacy

Poor Medication Adherence

• Present in 40% of patients 5
• Requires education, simplification of regimens, and regular monitoring 5

5. Preventive Interventions

Vaccinations

• Influenza vaccination reduces serious illness, death, and exacerbations 1
• Pneumococcal vaccines (PCV13 and PPSV23) recommended for all patients ≥65 years 1
• These decrease incidence of lower respiratory tract infections 1

Clinical Implementation Strategy

Phase 1: Initial Assessment (All Patients)

Address these traits in all COPD patients with smoking history 7:

• Current smoking status and cessation interventions
• Exacerbation frequency and severity
• Symptom burden (dyspnea, cough, sputum)
• Inhaler technique and adherence
• Vaccination status
• Basic comorbidity screening

Phase 2: Comprehensive Assessment (Advanced Disease)

For patients with persistent symptoms or disease progression despite Phase 1 interventions 7:

• Blood eosinophil count
• Nutritional assessment (BMI, sarcopenia screening)
• Formal psychological evaluation
• Physical activity assessment
• Detailed comorbidity evaluation
• Consider advanced interventions (oxygen therapy, non-invasive ventilation, lung volume reduction) 1

Key Clinical Considerations

Common pitfalls to avoid:

• Underestimating the impact of extra-pulmonary traits, particularly depression and nutritional status, which have stronger effects on outcomes than some pulmonary traits 3
• Focusing solely on pharmacotherapy while neglecting behavioral traits like inhaler technique (present in nearly half of patients) 5
• Missing the opportunity for smoking cessation interventions—this remains the only intervention that modifies disease trajectory 1

Critical insight: 83% of COPD patients have ≥1 treatable trait, and 49% have ≥2 traits occurring in various combinations 5. This heterogeneity mandates individualized assessment rather than one-size-fits-all approaches. Patients with treatable traits are younger, more socioeconomically deprived, and pose significant burden to primary care yet are rarely referred to specialists 2.